Nuclear targets are where an antibody's validation matters most, because abundance is low, the protein is in a compartment that fixation and extraction handle badly, and the most interesting form is usually a modified one. The questions repeat across the class: which application the clone was validated in, whether chromatin work needs a reagent qualified for immunoprecipitation, and whether the band or the signal is the protein rather than something the nucleus shares.
A jmjd3 antibody and a smarca4 antibody on chromatin
A demethylase and a remodeller ATPase are both large, low abundance nuclear proteins, and an antibody that works on a blot of an overexpressing lysate can fail on endogenous protein. For chromatin immunoprecipitation the reagent has to be qualified for it specifically, since crosslinking changes the epitope and a validated blot says nothing about pull down. Knockdown or knockout lysate beside wild type is the control that settles specificity, and it is worth running once per lot rather than trusting a catalogue image.
An ogt antibody and a ddb1 antibody on modification and ubiquitin machinery
O-GlcNAc transferase and the damage-specific DNA binding adaptor sit in complexes rather than alone, which matters twice: co-immunoprecipitation needs a gentle lysis that keeps the complex together, while a clean blot often needs a stringent one that pulls it apart. Both proteins are also degraded quickly in lysate at room temperature, so the sample handling decides whether a faint band is biology or proteolysis, and a protease inhibitor cocktail added at lysis is not optional.
An atm antibody and a blm antibody in the damage response
Damage response kinases and helicases are read by phosphorylation and localisation rather than by total abundance, so the useful reagents are phospho-specific clones against named residues plus a total antibody on the same membrane. Because the signal appears only after damage, a positive control matters: an irradiated or drug-treated lysate, harvested at the documented time point. Nuclear extraction is usually needed, since a whole cell lysate dilutes a nuclear protein below the blot's reach.
An mlh1 antibody and a trf2 antibody on repair and telomeres
Mismatch repair proteins are read in tissue as present or absent, which is a clinical shape of question and therefore demands a clone with a documented staining pattern, an internal positive control in the section, and careful retrieval, since a weak retrieval reads as loss. Telomere binding factors are the opposite problem: abundant enough to blot, and interesting mainly as foci, so the readout is immunofluorescence with a colocalisation control rather than a band.
An mycn antibody and a cyclin d antibody on the cell cycle
Both are short lived proteins degraded by the proteasome, so abundance moves within minutes and a lysate prepared slowly reports the handling. A proteasome inhibitor control shows the antibody can see the accumulated protein, which is the fastest way to separate a reagent problem from a biology one. Cyclin antibodies additionally have to state which cyclin and which isoform, since the family shares domains and a clone raised against a conserved region reports the family rather than the member.
A bax antibody and a bim antibody on apoptosis
Apoptosis regulators change conformation and location rather than amount at the moment they act, so the informative readouts are mitochondrial fractionation, a conformation-specific clone, or immunoprecipitation of the activated form. Both proteins run as several isoforms from alternative splicing, and a blot that shows one band where the literature shows three is usually a clone that sees one isoform. Positive controls come from a treated sample rather than from a healthy one.
An ar antibody and a gr antibody on nuclear receptors
Steroid receptors move between cytoplasm and nucleus with ligand, so the same antibody reports a different picture depending on when the cells were fixed, and the useful experiment states the hormone status of the culture. Receptor antibodies are also used to read variants: truncated androgen receptor forms require a clone whose epitope lies in a retained region, which is stated as the immunogen's position rather than as a name. Serum in the medium carries steroid, which is why charcoal stripped serum exists.
An nrf2 antibody and a klf2 antibody on stress and flow
Both are transcription factors whose antibodies have a poor reputation earned honestly: nuclear factor erythroid 2 related factor 2 is degraded constantly in unstressed cells and several widely cited clones detect an unrelated band at a similar size, so a knockdown control is the minimum evidence. Kruppel-like factors respond to shear and are low abundance, which means nuclear extracts and a positive control from a flow or statin treated sample. For both, cite the clone in the method, because the literature disagrees by clone.
Questions people ask about smyd3 antibody
What validates a nuclear target antibody?
Knockdown or knockout lysate beside wild type, in the application you will use. A blot on an overexpressing lysate proves very little about endogenous protein.
Can a blot-validated antibody be used for chromatin immunoprecipitation?
Not on that evidence. Crosslinking changes the epitope, so the reagent has to be qualified for pull down specifically.
Why do results differ between papers on the same target?
Because they differ by clone. For low abundance nuclear proteins the clone and lot belong in the method section.